Cambridge, Mass., Aug 27, 2026 – GentiBio, a clinical-stage biotechnology company advancing a pipeline of engineered regulatory T cell (EngTreg) therapies for autoimmune and inflammatory diseases, today announced publication of a research article demonstrating a powerful approach to enhance allogeneic EngTreg persistence, applicable to healthy-donor derived T cells and potentially other cell-based therapies.
Allogeneic cell therapies have the potential to improve patient access, manufacturing scalability, and product consistency compared with individualized autologous approaches. However, allogeneic cells face rejection by the host immune system, limiting their persistence and ability to provide durable therapeutic benefit. Removing HLA molecules can help prevent rejection by the adaptive immune system, but these HLA-deficient cells become vulnerable to natural killer (NK) cell-mediated “missing-self” recognition and elimination, representing a major hurdle to persistence.
The study describes a synthetic NKG2A engager designed to selectively engage an inhibitory NK cell pathway and protect HLA-deficient EngTregs from immune rejection. GentiBio researchers evaluated multiple approaches to NK cell inhibition and found that the synthetic NKG2A engager consistently outperformed commonly used immune evasive strategies in a stringent rejection model in vitro. Moreover, the publication demonstrates that HLA-deficient EngTregs expressing the synthetic engager achieved substantially improved resistance to NK cell-mediated rejection and persisted for at least 12 weeks in a humanized mouse model, while unprotected cells were rapidly eliminated. Therefore, this technology could enable long-lived allogeneic cell therapies with the potential for significant reduction in cost and improvements in patient access compared to autologous approaches.
“Achieving durable persistence remains one of the most important challenges facing allogeneic cell therapies,” said Tim (Tingxi) Guo, Ph.D., a lead author of the study. “The publication represents an important scientific milestone for GentiBio and our allogeneic EngTreg platform, supporting the feasibility of combining precise genetic engineering with targeted immune evasive technologies to create off-the-shelf Treg therapies capable of achieving a level of persistence that may lead to durable clinical benefit,” said Chris Moore, Ph.D., Director of Platform at GentiBio, who co-led this study.
To demonstrate translation, the publication reports that the technology was successfully integrated into an established engineering platform used to develop GentiBio’s clinical stage program. The company aims to leverage the approach in advancing its allogeneic EngTreg pipeline for autoimmune and inflammatory diseases and believes the technology could have broader applicability across other allogeneic cell therapy modalities where immune rejection remains a challenge.
The full article is available in EMBO Molecular Medicine.
About GentiBio
GentiBio is a biotechnology company developing engineered regulatory T cell (EngTreg) therapies to restore immune tolerance and transform the treatment of autoimmune and inflammatory diseases. GentiBio’s EngTregs harness the underlying power of Tregs and are engineered for precision, durability, and scalable manufacturing. GentiBio seeks to deliver disease modifying, and potentially curative, therapies for patients with significant unmet need. Learn more at Gentibio.com.
Contact
Media email: Hatem.Heikal@gentibio.com